Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

English (EN)·Polski (PL)·Ukraiński (UK)
Przejdź do strony domowej biblioteki Uniwersytet Ekonomiczny we Wrocławiu Link otwiera się w nowym oknie Logo biblioteki Prolib Integro - strona głównaUniwersytet Ekonomiczny we Wrocławiu

Wyszukujesz frazę ""Salvage Therapy"" wg kryterium: Temat

  Lista filtrów
Wyrównaj
Wyświetlanie 1-20 z 26704
Tytuł:
Salvage Therapy for Prostate Cancer: AUA/ASTRO/SUO Guideline Part II: Treatment Delivery for Non-metastatic Biochemical Recurrence After Primary Radical Prostatectomy.
Autorzy:
Morgan TM; Urology, University of Michigan, Ann Arbor, Michigan.
Boorjian SA; Urology, Mayo Clinic, Rochester, Minnesota.
Buyyounouski MK; Radiation Oncology, Stanford University, Stanford, California.
Chapin BF; Urology, University of Texas MD Anderson Cancer Center, Houston, Texas.
Chen DYT; Urology, Fox Chase Cancer Center-Temple Health, Rockledge, Pennsylvania.
Cheng HH; Division of Hematology and Oncology Medicine, University of Washington, Seattle, Washington.
Chou R; Pacific Northwest Evidence-based Practice Center, Portland, Oregon.
Jacene HA; Radiology, Harvard University, Boston, Massachusetts.
Kamran SC; Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.
Kim SK; American Urological Association, Linthicum, Maryland.
Kirkby E; American Urological Association, Linthicum, Maryland.
Luckenbaugh AN; Urology, Vanderbilt University, Nashville, Tennessee.
Nathanson BJ; AnCan, Teaneck, New Jersey.
Nyame YA; Urology, University of Washington, Seattle, Washington.
Posadas EM; Urologic Oncology, Cedars Sinai, Los Angeles, California.
Tran PT; Radiation Oncology, University of Maryland, Baltimore, Maryland.
Chen RC; Radiation Oncology, University of Kansas, Kansas City, Kansas.
Pokaż więcej
Źródło:
The Journal of urology [J Urol] 2024 Apr; Vol. 211 (4), pp. 518-525. Date of Electronic Publication: 2024 Feb 29.
Typ publikacji:
Journal Article; Practice Guideline
MeSH Terms:
Prostatic Neoplasms*/surgery
Prostatic Neoplasms*/pathology
Salvage Therapy*
Humans ; Male ; Neoplasm Recurrence, Local/surgery ; Prostate/pathology ; Prostate-Specific Antigen ; Prostatectomy ; Systematic Reviews as Topic
Czasopismo naukowe
Szczegóły
Tytuł:
Salvage Therapy for Prostate Cancer: AUA/ASTRO/SUO Guideline Part I: Introduction and Treatment Decision-Making at the Time of Suspected Biochemical Recurrence after Radical Prostatectomy.
Autorzy:
Morgan TM; Urology, University of Michigan, Ann Arbor, Michigan.
Boorjian SA; Urology, Mayo Clinic, Rochester, Minnesota.
Buyyounouski MK; Radiation Oncology, Stanford University, Stanford, California.
Chapin BF; Urology, University of Texas MD Anderson Cancer Center, Houston, Texas.
Chen DYT; Urology, Fox Chase Cancer Center-Temple Health, Rockledge, Pennsylvania.
Cheng HH; Division of Hematology and Oncology Medicine, University of Washington, Seattle, Washington.
Chou R; Pacific Northwest Evidence-based Practice Center, Portland, Oregon.
Jacene HA; Radiology, Harvard University, Boston, Massachusetts.
Kamran SC; Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.
Kim SK; American Urological Association, Linthicum, Maryland.
Kirkby E; American Urological Association, Linthicum, Maryland.
Luckenbaugh AN; Urology, Vanderbilt University, Nashville, Tennessee.
Nathanson BJ; AnCan, Teaneck, New Jersey.
Nyame YA; Urology, University of Washington, Seattle, Washington.
Posadas EM; Urologic Oncology, Cedars Sinai, Los Angeles, California.
Tran PT; Radiation Oncology, University of Maryland, Baltimore, Maryland.
Chen RC; Radiation Oncology, University of Kansas, Kansas City, Kansas.
Pokaż więcej
Źródło:
The Journal of urology [J Urol] 2024 Apr; Vol. 211 (4), pp. 509-517. Date of Electronic Publication: 2024 Feb 29.
Typ publikacji:
Journal Article; Practice Guideline
MeSH Terms:
Prostatic Neoplasms*/diagnosis
Prostatic Neoplasms*/surgery
Salvage Therapy*/methods
Humans ; Male ; Neoplasm Recurrence, Local/therapy ; Neoplasm Recurrence, Local/surgery ; Prostate/pathology ; Prostate-Specific Antigen ; Prostatectomy ; Systematic Reviews as Topic
Czasopismo naukowe
Szczegóły
Tytuł:
Salvage Therapy for Prostate Cancer: AUA/ASTRO/SUO Guideline Part III: Salvage Therapy After Radiotherapy or Focal Therapy, Pelvic Nodal Recurrence and Oligometastasis, and Future Directions.
Autorzy:
Morgan TM; Urology, University of Michigan, Ann Arbor, Michigan.
Boorjian SA; Urology, Mayo Clinic, Rochester, Minnesota.
Buyyounouski MK; Radiation Oncology, Stanford University, Stanford, California.
Chapin BF; Urology, University of Texas MD Anderson Cancer Center, Houston, Texas.
Chen DYT; Urology, Fox Chase Cancer Center-Temple Health, Rockledge, Pennsylvania.
Cheng HH; Division of Hematology and Oncology Medicine, University of Washington, Seattle, Washington.
Chou R; Pacific Northwest Evidence-based Practice Center, Portland, Oregon.
Jacene HA; Radiology, Harvard University, Boston, Massachusetts.
Kamran SC; Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.
Kim SK; American Urological Association, Linthicum, Maryland.
Kirkby E; American Urological Association, Linthicum, Maryland.
Luckenbaugh AN; Urology, Vanderbilt University, Nashville, Tennessee.
Nathanson BJ; AnCan, Teaneck, New Jersey.
Nyame YA; Urology, University of Washington, Seattle, Washington.
Posadas EM; Urologic Oncology, Cedars Sinai, Los Angeles, California.
Tran PT; Radiation Oncology, University of Maryland, Baltimore, Maryland.
Chen RC; Radiation Oncology, University of Kansas, Kansas City, Kansas.
Pokaż więcej
Źródło:
The Journal of urology [J Urol] 2024 Apr; Vol. 211 (4), pp. 526-532. Date of Electronic Publication: 2024 Feb 29.
Typ publikacji:
Journal Article; Practice Guideline
MeSH Terms:
Prostatic Neoplasms*/radiotherapy
Prostatic Neoplasms*/pathology
Salvage Therapy*/methods
Humans ; Male ; Neoplasm Recurrence, Local/therapy ; Prostate-Specific Antigen ; Prostatectomy ; Systematic Reviews as Topic
Czasopismo naukowe
Szczegóły
Tytuł:
Emergence of TP53 mutation during lenalidomide therapy of myelodysplastic syndrome with del(5q) and its subsequent disappearance following salvage therapy with decitabine.
Autorzy:
Gangat N; Mayo Clinic, Rochester, MN. .
Bellam N; Montgomery Cancer Center, Prattville Campus, Prattville, AL.
Reichard K; Mayo Clinic, Rochester, MN.
Tefferi A; Mayo Clinic, Rochester, MN. .
Pokaż więcej
Źródło:
Haematologica [Haematologica] 2024 Apr 01; Vol. 109 (4), pp. 1306-1309. Date of Electronic Publication: 2024 Apr 01.
Typ publikacji:
Case Reports; Journal Article
MeSH Terms:
Myelodysplastic Syndromes*/drug therapy
Myelodysplastic Syndromes*/genetics
Salvage Therapy*
Humans ; Chromosome Deletion ; Chromosomes, Human, Pair 5/genetics ; Decitabine/therapeutic use ; Lenalidomide/therapeutic use ; Mutation ; Tumor Suppressor Protein p53/genetics
Czasopismo naukowe
Szczegóły
Tytuł:
Amphotericin B deoxycholate instillations through nephrostomy catheter as salvage treatment of massive Nakaseomyces glabrata renal fungus balls.
Autorzy:
Le Moulec J; Infectious Diseases and Intensive Care Unit, Pontchaillou University Hospital, Rennes, France.
Picard L; Infectious Diseases and Intensive Care Unit, Pontchaillou University Hospital, Rennes, France.
Belaz S; Department of Parasitology and Mycology, Pontchaillou University Hospital, Rennes, France.
Couturier A; Infectious Diseases and Intensive Care Unit, Pontchaillou University Hospital, Rennes, France.
Revest M; Infectious Diseases and Intensive Care Unit, Pontchaillou University Hospital, Rennes, France.
Tattevin P; Infectious Diseases and Intensive Care Unit, Pontchaillou University Hospital, Rennes, France.
Luque-Paz D; Infectious Diseases and Intensive Care Unit, Pontchaillou University Hospital, Rennes, France. Electronic address: .
Pokaż więcej
Źródło:
Journal de mycologie medicale [J Mycol Med] 2024 Mar; Vol. 34 (1), pp. 101454. Date of Electronic Publication: 2023 Nov 17.
Typ publikacji:
Letter
MeSH Terms:
Salvage Therapy*
Antifungal Agents*/therapeutic use
Amphotericin B*
Deoxycholic Acid*
Catheters ; Nephrotomy ; Fungi ; Candida glabrata ; Drug Combinations
Opinia redakcyjna
Szczegóły
Tytuł:
Blinatumomab as salvage therapy in patients with relapsed/refractory B-ALL who have failed/progressed after anti-CD19-CAR T therapy.
Autorzy:
Qi Y; Department of Hematology, Tianjin First Central Hospital, School of Medicine, Nankai University, Tianjin, China.
Liu H; State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China.
Li X; Department of Hematology, Tianjin First Central Hospital, School of Medicine, Nankai University, Tianjin, China.
Shi Y; State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China.
Mu J; Department of Hematology, Tianjin First Central Hospital, School of Medicine, Nankai University, Tianjin, China.
Li J; Department of Hematology, Tianjin First Central Hospital, School of Medicine, Nankai University, Tianjin, China.
Wang Y; State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China.
Deng Q; Department of Hematology, Tianjin First Central Hospital, School of Medicine, Nankai University, Tianjin, China.
Pokaż więcej
Źródło:
Annals of medicine [Ann Med] 2023 Dec; Vol. 55 (1), pp. 2230888.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Coinfection*/drug therapy
Coinfection*/etiology
Precursor Cell Lymphoblastic Leukemia-Lymphoma*/drug therapy
Salvage Therapy*
Antibodies, Bispecific*/therapeutic use
Humans ; Antigens, CD19 ; CD8-Positive T-Lymphocytes ; Disease Progression ; Immunotherapy, Adoptive ; Receptors, Chimeric Antigen/therapeutic use
Czasopismo naukowe
Szczegóły
Tytuł:
Locoregional Recurrence of Esophageal Cancer Treated with Curative Intent Local Salvage Therapy: A Single Center Experience.
Autorzy:
Grou-Boileau F; Division of Thoracic and Upper Gastrointestinal Surgery, Montreal General Hospital, McGill University Health Centre, 1650 Cedar Avenue, Montreal, QC, Canada.
Tankel J; Division of Thoracic and Upper Gastrointestinal Surgery, Montreal General Hospital, McGill University Health Centre, 1650 Cedar Avenue, Montreal, QC, Canada.
Nevo Y; Division of Thoracic and Upper Gastrointestinal Surgery, Montreal General Hospital, McGill University Health Centre, 1650 Cedar Avenue, Montreal, QC, Canada.
Najmeh S; Division of Thoracic and Upper Gastrointestinal Surgery, Montreal General Hospital, McGill University Health Centre, 1650 Cedar Avenue, Montreal, QC, Canada.
Spicer J; Division of Thoracic and Upper Gastrointestinal Surgery, Montreal General Hospital, McGill University Health Centre, 1650 Cedar Avenue, Montreal, QC, Canada.
Cools-Lartigue J; Division of Thoracic and Upper Gastrointestinal Surgery, Montreal General Hospital, McGill University Health Centre, 1650 Cedar Avenue, Montreal, QC, Canada.
Mueller C; Division of Thoracic and Upper Gastrointestinal Surgery, Montreal General Hospital, McGill University Health Centre, 1650 Cedar Avenue, Montreal, QC, Canada.
Ferri L; Division of Thoracic and Upper Gastrointestinal Surgery, Montreal General Hospital, McGill University Health Centre, 1650 Cedar Avenue, Montreal, QC, Canada. .
Pokaż więcej
Źródło:
Journal of gastrointestinal cancer [J Gastrointest Cancer] 2023 Dec; Vol. 54 (4), pp. 1292-1299. Date of Electronic Publication: 2023 Mar 29.
Typ publikacji:
Journal Article
MeSH Terms:
Salvage Therapy*/methods
Esophageal Neoplasms*/pathology
Humans ; Neoplasm Staging ; Neoplasm Recurrence, Local/therapy ; Neoplasm Recurrence, Local/drug therapy ; Retrospective Studies ; Chemoradiotherapy ; Esophagectomy/methods ; Treatment Outcome
Czasopismo naukowe
Szczegóły
Tytuł:
Salvage treatment of acute respiratory failure after autogenous tissue flap transplantation for chronic empyema with chest wall sinus: a case report and literature review.
Autorzy:
Wang L; Department of Cardiothoracic Surgery, Tongde Hospital of Zhejiang Province, 234 Gucui Rd, Hangzhou, China.
Chen F; Department of Cardiothoracic Surgery, Tongde Hospital of Zhejiang Province, 234 Gucui Rd, Hangzhou, China. .
He Z; Department of Cardiothoracic Surgery, Tongde Hospital of Zhejiang Province, 234 Gucui Rd, Hangzhou, China.
He X; Department of Cardiothoracic Surgery, Tongde Hospital of Zhejiang Province, 234 Gucui Rd, Hangzhou, China.
Zhang C; Department of Traumatology and Orthopedic Surgery, Tongde Hospital of Zhejiang Province, 310012, Hangzhou, Zhejiang, China.
Pokaż więcej
Źródło:
Journal of cardiothoracic surgery [J Cardiothorac Surg] 2024 Jan 30; Vol. 19 (1), pp. 32. Date of Electronic Publication: 2024 Jan 30.
Typ publikacji:
Review; Case Reports; Journal Article
MeSH Terms:
Respiratory Distress Syndrome*/etiology
Respiratory Distress Syndrome*/therapy
Respiratory Insufficiency*/etiology
Respiratory Insufficiency*/therapy
Salvage Therapy*
Humans ; Male ; Middle Aged ; Bronchial Fistula/surgery ; Empyema, Pleural/complications ; Empyema, Pleural/surgery ; Pneumonectomy/adverse effects ; Thoracic Wall
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Healthcare resource utilization and costs during first salvage therapy for relapsed or refractory acute myeloid leukemia in the United States.
Autorzy:
Muffly L; Division of Blood and Marrow Transplantation and Cellular Therapy, Stanford University, Stanford, CA, USA.
Young C; Astellas Pharma, Inc, Northbrook, IL, USA.
Feng Q; Astellas Pharma, Inc, Northbrook, IL, USA.
Nimke D; Astellas Pharma, Inc, Northbrook, IL, USA.
Pandya BJ; Astellas Pharma, Inc, Northbrook, IL, USA.
Pokaż więcej
Źródło:
Leukemia & lymphoma [Leuk Lymphoma] 2023 Nov-Dec; Vol. 64 (11), pp. 1832-1839. Date of Electronic Publication: 2023 Jul 24.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Salvage Therapy*
Leukemia, Myeloid, Acute*/drug therapy
Humans ; United States/epidemiology ; Patient Acceptance of Health Care ; fms-Like Tyrosine Kinase 3 ; Mutation
Czasopismo naukowe
Szczegóły
Tytuł:
External validation of a risk model predicting failure of salvage focal ablation for prostate cancer.
Autorzy:
Light A; Imperial Prostate, Department of Surgery and Cancer, Imperial College London, London, UK.; Imperial Urology, Charing Cross Hospital, Imperial College Healthcare NHS Trust, London, UK.
Peters M; Department of Radiation Oncology, University Medical Center Utrecht, Utrecht, The Netherlands.
Reddy D; Imperial Prostate, Department of Surgery and Cancer, Imperial College London, London, UK.; Imperial Urology, Charing Cross Hospital, Imperial College Healthcare NHS Trust, London, UK.
Kanthabalan A; Division of Surgery and Interventional Sciences, University College London, London, UK.
Otieno M; Division of Surgery and Interventional Sciences, University College London, London, UK.
Pavlou M; Department of Statistical Science, University College London, London, UK.
Omar R; Department of Statistical Science, University College London, London, UK.
Adeleke S; Department of Oncology, Guy's and St Thomas' NHS Foundation Trust, London, UK.; School of Cancer and Pharmaceutical Sciences, King's College London, London, UK.
Giganti F; Division of Surgery and Interventional Sciences, University College London, London, UK.; Department of Radiology, University College London Hospital NHS Foundation Trust, London, UK.
Brew-Graves C; Division of Medicine, Faculty of Medicine, University College London, London, UK.
Williams NR; Division of Surgery and Interventional Sciences, University College London, London, UK.
Emara A; Department of Urology, Basingstoke and North Hampshire Hospital, Hampshire Hospitals NHS Foundation Trust, Basingstoke, UK.
Haroon A; Institute of Nuclear Medicine, University College London Hospitals NHS Foundation Trust, London, UK.; Department of Nuclear Medicine, St Bartholomew's Hospital, Barts Health NHS Trust, London, UK.
Latifoltojar A; Division of Medicine, Faculty of Medicine, University College London, London, UK.; Department of Radiology, Royal Marsden NHS Foundation Trust, Surrey, UK.
Sidhu H; Division of Medicine, Faculty of Medicine, University College London, London, UK.; Department of Radiology, University College London Hospital NHS Foundation Trust, London, UK.
Freeman A; Department of Histopathology, University College London Hospital NHS Foundation Trust, London, UK.
Orczyk C; Division of Surgery and Interventional Sciences, University College London, London, UK.; Department of Urology, University College London Hospital NHS Foundation Trust, London, UK.
Nikapota A; Sussex Cancer Centre, Royal Sussex County Hospital, University Hospitals Sussex NHS Foundation Trust, Brighton, UK.
Dudderidge T; Department of Urology, University Hospital Southampton NHS Foundation Trust, Southampton, UK.
Hindley RG; Department of Urology, Basingstoke and North Hampshire Hospital, Hampshire Hospitals NHS Foundation Trust, Basingstoke, UK.
Virdi J; Department of Urology, The Princess Alexandra Hospital NHS Trust, Harlow, UK.
Arya M; Imperial Urology, Charing Cross Hospital, Imperial College Healthcare NHS Trust, London, UK.
Payne H; Department of Histopathology, University College London Hospital NHS Foundation Trust, London, UK.
Mitra AV; Department of Oncology, University College London Hospital NHS Foundation Trust, London, UK.
Bomanji J; Institute of Nuclear Medicine, University College London Hospitals NHS Foundation Trust, London, UK.
Winkler M; Imperial Prostate, Department of Surgery and Cancer, Imperial College London, London, UK.; Imperial Urology, Charing Cross Hospital, Imperial College Healthcare NHS Trust, London, UK.
Horan G; Department of Oncology, Queen Elizabeth Hospital, The Queen Elizabeth Hospital King's Lynn NHS Foundation Trust, King's Lynn, UK.
Moore C; Division of Surgery and Interventional Sciences, University College London, London, UK.; Department of Urology, University College London Hospital NHS Foundation Trust, London, UK.
Emberton M; Division of Surgery and Interventional Sciences, University College London, London, UK.; Department of Urology, University College London Hospital NHS Foundation Trust, London, UK.
Punwani S; Division of Medicine, Faculty of Medicine, University College London, London, UK.; Department of Radiology, University College London Hospital NHS Foundation Trust, London, UK.
Ahmed HU; Imperial Prostate, Department of Surgery and Cancer, Imperial College London, London, UK.; Imperial Urology, Charing Cross Hospital, Imperial College Healthcare NHS Trust, London, UK.; Division of Surgery and Interventional Sciences, University College London, London, UK.
Shah TT; Imperial Prostate, Department of Surgery and Cancer, Imperial College London, London, UK.; Imperial Urology, Charing Cross Hospital, Imperial College Healthcare NHS Trust, London, UK.; Division of Surgery and Interventional Sciences, University College London, London, UK.
Pokaż więcej
Źródło:
BJU international [BJU Int] 2023 Nov; Vol. 132 (5), pp. 520-530. Date of Electronic Publication: 2023 Jun 29.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't; Research Support, N.I.H., Extramural
MeSH Terms:
Prostatic Neoplasms*/surgery
Prostatic Neoplasms*/radiotherapy
Salvage Therapy*/adverse effects
Humans ; Male ; Biopsy ; Brachytherapy ; Neoplasm Recurrence, Local ; Prospective Studies ; Treatment Outcome ; Multicenter Studies as Topic ; Clinical Trials as Topic
Czasopismo naukowe
Szczegóły
Tytuł:
FLT3 inhibitors as MRD-guided salvage treatment for molecular failure in FLT3 mutated AML.
Autorzy:
Othman J; Department of Medical and Molecular Genetics, King's College London, London, England, UK.; Guy's and St Thomas' NHS Foundation Trust, London, England, UK.; Faculty of Medicine and Health, University of Sydney, Sydney, NSW, Australia.
Potter N; Department of Medical and Molecular Genetics, King's College London, London, England, UK.
Mokretar K; Cancer Genetics, Synnovis, London, England, UK.
Taussig D; The Royal Marsden NHS Foundation Trust, London, England, UK.
Khan A; Leeds Teaching Hospitals NHS Trust, Leeds, England, UK.
Krishnamurthy P; King's College Hospital, London, England, UK.
Latif AL; Queen Elizabeth University Hospital, Glasgow, Scotland, UK.
Cahalin P; Blackpool Teaching Hospitals NHS Foundation Trust, Blackpool, England, UK.
Aries J; Barts Cancer Institute, Queen Mary University of London, London, England, UK.
Amer M; University Hospital Southampton, Southampton, England, UK.
Belsham E; Portsmouth Hospitals NHS Trust, Portsmouth, England, UK.
Conneally E; St. James's Hospital, Dublin, Ireland.
Craddock C; University Hospital Birmingham, Birmingham, England, UK.
Culligan D; Aberdeen Royal Infirmary, Aberdeen, Scotland, UK.
Dennis M; The Christie NHS Foundation Trust, Manchester, England, UK.
Duncan C; Raigmore Hospital, Inverness, Scotland, UK.
Freeman SD; Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, Scotland, UK.
Furness C; The Royal Marsden NHS Foundation Trust, London, England, UK.
Gilkes A; Department of Haematology, Cardiff University, Cardiff, Wales, UK.
Gkreka P; Princess Royal University Hospital, London, England, UK.
Hodgson K; University Hospital Leicester, Leicester, England, UK.
Ingram W; University Hospital Wales, Cardiff, Wales, UK.
Jain M; Leeds Teaching Hospitals NHS Trust, Leeds, England, UK.
King A; Addenbrooke's Hospital, Cambridge, England, UK.
Knapper S; School of Medicine, Cardiff University, Cardiff, Wales, UK.
Kottaridis P; University College London Hospital NHS Foundation Trust, London, England, UK.
McMullin MF; Queen's University, Belfast, Northern Ireland, UK.
Mohite U; Singleton Hospital, Sketty, Wales, UK.
Ngu L; Royal Devon & Exeter NHS Foundation Trust, Exeter, England, UK.
O'Nions J; University College London Hospital NHS Foundation Trust, London, England, UK.
Patrick K; Sheffield Childrens NHS Foundation Trust, Sheffield, England, UK.
Rider T; The Royal Sussex County Hospital, Brighton and Hove, England, UK.
Roberts W; Great North Children's Hospital, Newcastle upon Tyne, England, UK.
Severinsen MT; Department of Hematology, Clinical Cancer Research Center, Aalborg University Hospital, Aalborg, Denmark.
Storrar N; NHS Lothian, Edinburgh, Scotland, UK.
Taylor T; Nottingham University Hospital, Nottingham, England, UK.
Russell NH; Guy's and St Thomas' NHS Foundation Trust, London, England, UK.
Dillon R; Department of Medical and Molecular Genetics, King's College London, London, England, UK. .; Guy's and St Thomas' NHS Foundation Trust, London, England, UK. .
Pokaż więcej
Źródło:
Leukemia [Leukemia] 2023 Oct; Vol. 37 (10), pp. 2066-2072. Date of Electronic Publication: 2023 Aug 09.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Leukemia, Myeloid, Acute*/drug therapy
Leukemia, Myeloid, Acute*/genetics
Salvage Therapy*
Humans ; fms-Like Tyrosine Kinase 3/antagonists & inhibitors ; fms-Like Tyrosine Kinase 3/genetics ; Mutation ; Neoplasm Recurrence, Local ; Prospective Studies ; Protein Kinase Inhibitors/therapeutic use
Czasopismo naukowe
Szczegóły
Tytuł:
Functional and quality-of-life outcomes following salvage surgery for recurrent squamous cell carcinoma of the head and neck: a systematic review and meta-analysis.
Autorzy:
Williamson A; International Centre for Recurrent Head and Neck Cancer (IReC), Department of Head and Neck Surgery, The Royal Marsden Hospital, London, UK. .; Institute for Cancer Research, London, UK. .
Jashek-Ahmed F; International Centre for Recurrent Head and Neck Cancer (IReC), Department of Head and Neck Surgery, The Royal Marsden Hospital, London, UK.; London School of Hygiene and Tropical Medicine, London, UK.
Hardman J; International Centre for Recurrent Head and Neck Cancer (IReC), Department of Head and Neck Surgery, The Royal Marsden Hospital, London, UK.; Institute for Cancer Research, London, UK.
Paleri V; International Centre for Recurrent Head and Neck Cancer (IReC), Department of Head and Neck Surgery, The Royal Marsden Hospital, London, UK.; Institute for Cancer Research, London, UK.
Pokaż więcej
Źródło:
European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery [Eur Arch Otorhinolaryngol] 2023 Oct; Vol. 280 (10), pp. 4597-4618. Date of Electronic Publication: 2023 Jun 17.
Typ publikacji:
Meta-Analysis; Systematic Review; Journal Article
MeSH Terms:
Head and Neck Neoplasms*/surgery
Salvage Therapy*/methods
Squamous Cell Carcinoma of Head and Neck*/surgery
Humans ; Quality of Life ; Neoplasm Recurrence, Local
Czasopismo naukowe
Szczegóły
Tytuł:
Surveillance imaging for salvage therapy in endometrial cancer.
Autorzy:
Barry P; Radiation Oncology, UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, USA .
Beriwal S; Radiation Oncology, Allegheny Health Network, Pittsburgh, Pennsylvania, USA.; Vice President, Varian Systems, Palo Alto, California, USA.
Maheshwari E; Radiology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
Bhargava R; Pathology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
Small W Jr; Radiation Oncology, Cardinal Bernardin Cancer Center, Loyola University Chicago Stritch School of Medicine, Maywood, Illinois, USA.
Pokaż więcej
Źródło:
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society [Int J Gynecol Cancer] 2023 Sep 04; Vol. 33 (9), pp. 1464-1468. Date of Electronic Publication: 2023 Sep 04.
Typ publikacji:
Journal Article
MeSH Terms:
Salvage Therapy*
Endometrial Neoplasms*/diagnostic imaging
Endometrial Neoplasms*/therapy
Humans ; Female ; Diagnostic Imaging
Czasopismo naukowe
Szczegóły
Tytuł:
Patterns of treatment failure in patients with nasopharyngeal carcinoma and salvage treatment outcome: A retrospective analysis study.
Autorzy:
Aldhahri SF; Department of Otolaryngology-Head and Neck Surgery, College of Medicine, King Saud University, Riyadh, Saudi Arabia; Department of Otolaryngology-Head and Neck Surgery, King Fahad Medical City, Riyadh, Saudi Arabia. Electronic address: .
Barakeh MM; College of Medicine, King Saud University, Riyadh, Saudi Arabia.
Almetary RJ; College of Medicine, King Saud University, Riyadh, Saudi Arabia.
Alfirm RB; College of Medicine, King Saud University, Riyadh, Saudi Arabia.
Almousa HM; College of Medicine, King Saud University, Riyadh, Saudi Arabia.
Alsubaie HM; Department of Otolaryngology-Head and Neck Surgery, King Abdullah Medical City, Makkah, Saudi Arabia.
Pokaż więcej
Źródło:
American journal of otolaryngology [Am J Otolaryngol] 2023 Sep-Oct; Vol. 44 (5), pp. 103941. Date of Electronic Publication: 2023 Jun 07.
Typ publikacji:
Journal Article
MeSH Terms:
Salvage Therapy*
Nasopharyngeal Neoplasms*/pathology
Humans ; Nasopharyngeal Carcinoma/therapy ; Nasopharyngeal Carcinoma/pathology ; Retrospective Studies ; Neoplasm Staging ; Follow-Up Studies ; Treatment Outcome ; Chemoradiotherapy/adverse effects ; Treatment Failure
Czasopismo naukowe
Szczegóły
Tytuł:
Endobronchial Valve Placement as Salvage Therapy in the Management of Hemoptysis.
Autorzy:
Frey JW; Division of Pulmonary and Critical Care Medicine, University of Kansas School of Medicine, Kansas City, KS.
Postigo M
Pitts LR
Pokaż więcej
Źródło:
Journal of bronchology & interventional pulmonology [J Bronchology Interv Pulmonol] 2023 Jul 01; Vol. 30 (3), pp. 301-303. Date of Electronic Publication: 2023 Jul 01.
Typ publikacji:
Letter
MeSH Terms:
Salvage Therapy*
Hemoptysis*/etiology
Hemoptysis*/surgery
Humans ; Bronchoscopy ; Prostheses and Implants
Opinia redakcyjna
Szczegóły
Tytuł:
Salvage treatment after extravasation of chemotherapy agents: A rare case report.
Autorzy:
Guo Y; Department of Breast and Thyroid Surgery, The Third Affiliated Hospital of Zunyi Medical University (The First People's Hospital of Zunyi), Zunyi, Guizhou, China.
Huo J; Department of Breast and Thyroid Surgery, The Third Affiliated Hospital of Zunyi Medical University (The First People's Hospital of Zunyi), Zunyi, Guizhou, China. Electronic address: .
Pokaż więcej
Źródło:
Asian journal of surgery [Asian J Surg] 2023 Jul; Vol. 46 (7), pp. 2750-2751. Date of Electronic Publication: 2023 Jan 17.
Typ publikacji:
Case Reports; Letter
MeSH Terms:
Salvage Therapy*
Antineoplastic Agents*/adverse effects
Humans ; Antineoplastic Combined Chemotherapy Protocols/adverse effects
Raport
Szczegóły
Tytuł:
Salvage Therapy in Acute Severe Ulcerative Colitis: Current Practice and a Look to the Future.
Autorzy:
Tamir-Degabli N; Department of Gastroenterology and Liver Diseases, Tel Aviv Medical Center, Tel Aviv, Israel; Tel Aviv University Sackler Faculty of Medicine, Tel Aviv, Israel.
Maharshak N; Department of Gastroenterology and Liver Diseases, Tel Aviv Medical Center, Tel Aviv, Israel; Tel Aviv University Sackler Faculty of Medicine, Tel Aviv, Israel.
Cohen NA; Department of Gastroenterology and Liver Diseases, Tel Aviv Medical Center, Tel Aviv, Israel; Tel Aviv University Sackler Faculty of Medicine, Tel Aviv, Israel.
Pokaż więcej
Źródło:
The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology [Turk J Gastroenterol] 2023 Jun; Vol. 34 (6), pp. 576-583.
Typ publikacji:
Review; Journal Article
MeSH Terms:
Salvage Therapy*
Colitis, Ulcerative*/drug therapy
Humans ; Artificial Intelligence ; Quality of Life ; Infliximab/therapeutic use
Czasopismo naukowe
Szczegóły
Tytuł:
Efficacy of salvage therapies after failure of adjuvant anti-PD-1 monotherapy for melanoma in the Chinese population: a multi-institutional cohort study.
Autorzy:
Jia DD; Department of Bone and Soft-tissue Surgery, The Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Institute of Basic Medicine and Cancer (IBMC), Chinese Academy of Sciences, Hangzhou, Zhejiang, 310022, China.
Xu Y; Department of Musculoskeletal Surgery, Department of Oncology, Fudan University Shanghai Cancer Center, Shanghai Medical College, Fudan University, Shanghai, 200032, China.
Li T; Departments of Bone and Soft Tissue Tumour, Tianjin Medical University Cancer Institute and Hospital, Tianjin, 300060, China.
Yang JL; Departments of Bone and Soft Tissue Tumour, Tianjin Medical University Cancer Institute and Hospital, Tianjin, 300060, China. .
Chen Y; Department of Musculoskeletal Surgery, Department of Oncology, Fudan University Shanghai Cancer Center, Shanghai Medical College, Fudan University, Shanghai, 200032, China. .
Li T; Department of Bone and Soft-tissue Surgery, The Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Institute of Basic Medicine and Cancer (IBMC), Chinese Academy of Sciences, Hangzhou, Zhejiang, 310022, China. .
Pokaż więcej
Źródło:
Investigational new drugs [Invest New Drugs] 2023 Jun; Vol. 41 (3), pp. 431-437. Date of Electronic Publication: 2023 Apr 24.
Typ publikacji:
Multicenter Study; Journal Article
MeSH Terms:
Melanoma*/drug therapy
Salvage Therapy*
Skin Neoplasms*/drug therapy
Humans ; Adjuvants, Immunologic/therapeutic use ; Cohort Studies ; East Asian People ; Neoplasm Recurrence, Local/drug therapy ; Proto-Oncogene Proteins B-raf ; Retrospective Studies ; Melanoma, Cutaneous Malignant
Czasopismo naukowe
Szczegóły
Tytuł:
Fosfomycin as salvage therapy for persistent methicillin-resistant Staphylococcus aureus bacteremia: A case series and review of the literature.
Autorzy:
Omori K; Department of Infectious Diseases, Hiroshima University Hospital, Hiroshima, Japan; Department of Molecular and Internal Medicine, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan; Division of Infection Control, Hiroshima University Hospital, Hiroshima, Japan. Electronic address: .
Kitagawa H; Department of Infectious Diseases, Hiroshima University Hospital, Hiroshima, Japan; Division of Infection Control, Hiroshima University Hospital, Hiroshima, Japan; Department of Surgery, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.
Takada M; Division of Pharmacy, National Hospital Organization, Kure Medical Center and Chugoku Cancer Center, Hiroshima, Japan.
Maeda R; Division of Pharmacy, National Hospital Organization, Kure Medical Center and Chugoku Cancer Center, Hiroshima, Japan.
Nomura T; Department of Infectious Diseases, Hiroshima University Hospital, Hiroshima, Japan; Division of Infection Control, Hiroshima University Hospital, Hiroshima, Japan.
Kubo Y; Division of Infection Control, Hiroshima University Hospital, Hiroshima, Japan.
Shigemoto N; Department of Infectious Diseases, Hiroshima University Hospital, Hiroshima, Japan; Division of Infection Control, Hiroshima University Hospital, Hiroshima, Japan; Department of Surgery, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan; Translational Research Center, Hiroshima University, Hiroshima, Japan.
Ohge H; Department of Infectious Diseases, Hiroshima University Hospital, Hiroshima, Japan; Division of Infection Control, Hiroshima University Hospital, Hiroshima, Japan.
Pokaż więcej
Źródło:
Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy [J Infect Chemother] 2024 Apr; Vol. 30 (4), pp. 352-356. Date of Electronic Publication: 2023 Nov 03.
Typ publikacji:
Review; Case Reports
MeSH Terms:
Methicillin-Resistant Staphylococcus aureus*
Fosfomycin*/therapeutic use
Bacteremia*/drug therapy
Daptomycin*/therapeutic use
Male ; Female ; Humans ; Aged, 80 and over ; Middle Aged ; Salvage Therapy ; Linezolid
Recenzja
Szczegóły
Tytuł:
Nelarabine-containing salvage therapy and conditioning regimen in transplants for pediatric T-cell acute lymphoblastic leukemia and lymphoma.
Autorzy:
Yanagi M; Department of Hematology/Oncology, Saitama Children's Medical Center, Saitama, Japan. .; Department of Hematology/Oncology for Children and Adolescents, Sapporo Hokuyu Hospital, Higashi-Sapporo 6-6, Shiroishi-ku, Sapporo, 003-0006, Japan. .
Mori M; Department of Hematology/Oncology, Saitama Children's Medical Center, Saitama, Japan.
Honda M; Department of Hematology/Oncology, Saitama Children's Medical Center, Saitama, Japan.
Mitani Y; Department of Hematology/Oncology, Saitama Children's Medical Center, Saitama, Japan.
Seki M; Department of Hematology/Oncology, Saitama Children's Medical Center, Saitama, Japan.
Fukuoka K; Department of Hematology/Oncology, Saitama Children's Medical Center, Saitama, Japan.
Oshima K; Department of Hematology/Oncology, Saitama Children's Medical Center, Saitama, Japan.
Arakawa Y; Department of Hematology/Oncology, Saitama Children's Medical Center, Saitama, Japan.
Koh K; Department of Hematology/Oncology, Saitama Children's Medical Center, Saitama, Japan.
Pokaż więcej
Źródło:
International journal of hematology [Int J Hematol] 2024 Mar; Vol. 119 (3), pp. 327-333. Date of Electronic Publication: 2024 Feb 01.
Typ publikacji:
Journal Article
MeSH Terms:
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma*/drug therapy
Precursor Cell Lymphoblastic Leukemia-Lymphoma*/drug therapy
Lymphoma*
Hematopoietic Stem Cell Transplantation*/methods
Arabinonucleosides*
Humans ; Child ; Salvage Therapy ; Retrospective Studies ; T-Lymphocytes
Czasopismo naukowe
Szczegóły
Wyświetlanie 1-20 z 26704

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies